Skip to Content

Join the 'Aprepitant' group to help and get support from people like you.

Aprepitant News

FDA Approves Pediatric Indication for Emend (aprepitant) Capsules in Combination with Other Antiemetic Agents

Posted 2 Sep 2015 by

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Emend (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. With this expanded indication, Emend capsules are now approved for use in combination with other antiemetic agents in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg (approximately 66 pounds) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin, as well as for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Emend has not been ... Read more

Related support groups: Nausea/Vomiting - Chemotherapy Induced, Emend, Aprepitant

Ask a Question

Further Information

Related Condition Support Groups

Nausea / Vomiting - Chemotherapy Induced, Nausea / Vomiting - Postoperative

Related Drug Support Groups

Emend, Emend 3-Day, Emend 2-Day

Aprepitant Patient Information at